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According to the World Cancer Report of 2014,[1] lung cancer 
remains the most common cause of cancer-related death, resulting 
in >1.59 million reported deaths in 2012. The situation in South 
Africa (SA) is no different, although studies have consistently 
shown that SA patients with non-small-cell lung cancer (NSCLC) 
have an inferior potential cure rate at presentation when compared 
with the USA and Western Europe.[2-4] Only ~10% of patients 
diagnosed with lung cancer in SA are offered treatment with 
curative intent.[2-4]
The National Institute for Health and Clinical Excellence (NICE) 
guideline[5] recommends radical surgery for stage I - II NSCLC, with 
chemoradiotherapy with or without surgery (with curative intent) 
offered to patients with stage IIIA disease. Palliative chemotherapy 
and radiotherapy are recommended for later-stage NSCLC patients 
(stage IIIB and IV).[5] Stage at diagnosis is therefore an important 
indicator of survival in lung cancer.[6] Diagnosis at an advanced 
stage (IIIB or IV) usually precludes the possibility of cure and leads 
to poor long-term outcomes.[7-9] Five-year survival rates of patients 
diagnosed with late-stage disease range from ~4% to 6%, whereas 
those for early-stage disease range from 40% to 54%.[6,10-14]
Health insurance status is commonly used as a surrogate marker 
of socioeconomic status (SES).[15] In turn, SES has been shown to 
be an independent contributor to health status, as a surrogate for 
lifestyle, diet, and working and living conditions.[16] Lower SES is 
known to be associated not only with an increased incidence of 
cancer but also with worsened survival.[17,18] Although numerous 
studies across various cancers have shown that poor SES has been 
associated with late-stage diagnosis, this has not been consistently 
observed in studies looking at NSCLC in isolation.[18-21] Disparities 
in access to healthcare and its use, as well as lack of preventive 
healthcare services including cancer screening, may contribute 
somewhat to differentials in cancer stage distributions, especially in 
late-stage diagnosis.[18,22-25]
Objective
There is a paucity of SA data comparing the staging of lung cancer 
patients at the time of presentation based on SES. The objective of 
this study was to assess the relationship between health insurance 
status (and invariably SES) and staging of patients (and therefore 
resectability and potential cure) with primary NSCLC at the time of 
initial presentation. The study’s null hypothesis, based on previous 
international research, was that there is no notable difference in the 
resectability rates of patients with v. without private health insurance 
diagnosed with NSCLC at the time of presentation.
Methods
All cases of primary lung cancer presenting to Tygerberg Academic 
Hospital and the Kuils River Respiratory Centre (Kuils River Hospital) 
in Cape Town, SA, between August 2013 and September 2015 were 
identified. Tygerberg Academic Hospital, a 1 380-bed public hospital, 
is a primary referral centre serving approximately three million 
people. Kuils River Respiratory Centre is based in the suburb of 
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Kuils River, with patients being admitted 
to the 180-bed Kuils River Hospital.[26] 
The two centres are in close proximity and 
serve a patient population group similar in 
demographics other than their SES.
All patients in the study population 
diagnosed with an underlying primary 
NSCLC in either of the institutions were 
included in the study group. In the study 
group, all patients who had a confirmed 
histological diagnosis together with complete 
staging details were included in the analysis. 
Patients were excluded if the presentation 
with primary lung malignancy was not their 
first presentation to the healthcare service 
with a malignancy, or if a second underlying 
malignancy was suspected at the time of 
presentation.
Information on individual patients was 
collected retrospectively from medical 
records, including routine demographic and 
clinical data. All patients had access to 
positron emission tomography/computed 
tomography, bronchoscopy with endobron-
chial ultrasound-guided transbronchial 
needle aspiration with rapid on-site evalu-
ation, transthoracic image (ultrasound or 
tomography)-guided biopsy and related 
diagnostic techniques that were performed 
at the discretion of the treating doctors 
as per standard operating procedures. A 
combined panel of at least a pulmonolo-
gist, thoracic radiologist, thora cic surgeon, 
specialist oncologist and pathologist staged 
all patients as per the 2009 International 
Association for the Study of Lung Cancer 
tumour node metastasis (TNM) staging 
system. These findings were recorded pro-
spectively in a lung cancer registry (admin-
istered by the investigators), which was 
retrospectively used to identify cases anony-
mously.
Pathological analyses were performed by 
the National Health Laboratory Services 
at Tygerberg Hospital (state patients) and 
Ampath Laboratories at N1 City Hospital in 
Cape Town (insured patients).
Statistical analysis
Data were collected on a customised 
Microsoft Excel spreadsheet, version 
15.0.4797.1000 (Microsoft, USA). Chi-square 
or Fisher’s exact tests (where indicated) were 
performed on dichotomous categorical 
variables, and t-testing on continuous data. 
A 5% significance level (p<0.05) was applied.
Ethical approval
Ethical approval for this retrospective 
analysis was provided by the Stellenbosch 
University Research Ethics Committee (ref. 
no. S16/04/077). The application included a 
waiver of consent owing to the retrospective 
nature and anonymity of the study design.
Results
During the 2-year study period, 665 patients 
were seen between the two institutions 
with a confirmed histological diagnosis of 
primary lung malignancy. All the patients 
who presented to Tygerberg Hospital 
(n=610) had no health insurance, whereas 
all the patients who presented to Kuils River 
Respiratory Centre (n=55) had access to 
private health insurance.
The patients with no health insurance 
were younger (mean (standard deviation 
(SD)) 59.9 (10.1) years) than those with 
private health insurance (64.15 (9.6) years) 
(p=0.03). There was no significant difference 
in gender distribution between the two 
groups (Table 1). Overall, adenocarcinoma 
was the commonest form of lung malignancy 
(48.1%), followed by squamous cell carcin-
oma (29.2%). In the privately health-insured 
group, poorly differentiated NSCLC (25.5%) 
was more common than squamous cell 
carcinoma (23.6%). Poorly differentiated 
NSCLC was also significantly more common 
in the privately health-insured group (23.6%) 
compared with those with no health insur-
ance (4.6%) (p<0.01).
Sixty-one (10.5%) of the 583 patients with 
NSCLC were staged as early-stage disease 
(up to stage IIIA, Table 1). In total, 477 of 
532 NSCLC state patients (89.7%) had incur-
able disease at presentation, compared with 
45 of 51 privately insured patients (88.8%) 
(p=0.75). Conversely, 55 state patients 
(10.3%) presented with early-stage, poten-
tially curable disease (up to stage IIIA) com-
pared with 6 patients in the privately insured 
group (11.8%) (p=0.75).
Discussion
In this retrospective, observational study 
in patients with NSCLC, access to private 
health insurance (medical aid in SA) was 
shown not to have a significant effect on 
staging at initial presentation. The only 
significant differences were the relatively 
advanced age at presentation and relatively 
higher percentage of poorly differentiated 
NSCLC seen in private practice.
Potential theories regarding why a later-
stage diagnosis would have been expected in 
Table 1. Demographics, cell types and staging for all lung cancer patients by health 
insurance type (N=665)
All*
(N=665)
No health 
insurance
(n=610)
Private health 
insurance
(n=55) p-value
Demographics 
Age (yr), mean (SD) 60.49 (10.1) 59.9 (10.1) 64.15 (9.6) 0.03
Gender male, n (%) 404 (60.8) 372 (61.0) 32 (58.2) 0.68
Cell type, n (%)
NSCLC (n=583)
Adenocarcinoma 320 (48.1) 298 (48.9) 22 (40.0) 0.26
Squamous cell carcinoma 194 (29.2) 181 (29.7) 13 (23.6) 0.35
Poorly differentiated 42 (6.3) 28 (4.6) 14 (25.5) <0.01
Other 27 (4.1) 25 (4.1) 2 (3.6) 1
SCLC 82 (12.3) 78 (12.8) 4 (7.3) 0.28
Stage, n (%)
NSCLC (n=583)
I 8 (1.4) 7 (1.3) 1 (2.0) 1
II 15 (2.6) 15 (2.8) 0 (0.0) 0.38
IIIA 38 (6.5) 33 (6.2) 5 (9.8) 0.37
IIIB 128 (22.0) 115 (21.6) 13 (25.5) 0.52
IV 394 (67.6) 362 (68.0) 32 (62.7) 0.44
SCLC (n=82)
Limited 11 (13.4) 10 (12.8) 1 (25.0) 1
Extensive 71 (86.6) 68 (87.2) 3 (75.0) 1
SD = standard deviation; NSCLC = non-small-cell lung cancer; SCLC = small-cell lung cancer.
*Stage I - IIIA v. stages IIIB - IV NSCLC.
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those of lower SES include fatalistic views and medical mistrust, which 
has been shown to be more common among the poor and minorities[27,28] 
and leads to delays in seeking care for symptoms suggestive of lung 
cancer as well as delaying prompt work-up once a tumour has been 
identified. The poor may also prioritise health to a lesser degree and 
therefore postpone seeing a doctor, which can contribute to later stage of 
presentation.[6,28] However, these findings were not reproducible in this 
study, which showed that although patients without health insurance 
presented with later-stage disease, there was no significant difference 
between the privately insured and uninsured groups.
A systematic review of the literature from 1995 to 2005 by Woods 
et al.[15] found that most studies report an association between low 
SES and later stage at diagnosis of various cancers. As with our 
study, this does not always hold true when looking at NSCLC in 
isolation. Various studies of lung cancer from Canada, Denmark and 
Sweden have only indicated limited socioeconomic differences in 
advanced-stage diagnosis.[17,29,30] Other studies from the UK have in 
fact shown a lower frequency of advanced stage at diagnosis in more 
deprived patients.[31] The findings of our study, although not showing 
independent evidence of an association (p=0.75), may reflect a lack 
of power due to the lack of numbers in the privately insured group. 
To our knowledge, there are no available local data looking at the 
influence of SES or health insurance on the stage of presentation of 
primary lung malignancy.
The proportion of early-stage (up to stage IIIA) disease in the study 
group was calculated at 10.3% in our patients with no health insurance 
and 11.8% in those with private health insurance. This corresponds 
with reported resectability rates in patients with NSCLC in SA 
literature, where operability rates between 10% and 11% have been 
quoted in other studies from Johannesburg and Cape Town.[2-4,32,33] 
In the developed world, the proportion of patients who present with 
potentially curable disease is much higher. A study detailing >12 800 
cases of lung cancer from Nebraska, Canada, revealed early-stage 
disease in 23.04% of patients.[34] Other studies from the developed 
world have revealed resectable disease in up to 33% of patients.[13] 
It must be noted that in the SA setting, other factors including the 
effect of the HIV pandemic on the stage of presentation must be 
kept in mind. A previous study from the Western Cape Province, SA, 
has shown that HIV-positive lung cancer patients were significantly 
less likely to have early-stage lung cancer compared with their HIV-
negative counterparts.[4] Limited resources in the state sector and 
restricted funding by medical aids in the private sector also pose 
significant barriers to early detection of disease.
The present study revealed that poorly differentiated NSCLC was 
significantly more common in the privately health-insured group 
(23.6%) compared with those with no health insurance (4.6%) 
(p<0.01). Our data also support current worldwide lung cancer trends 
that have revealed an increase in the proportion of patients being 
diagnosed with adenocarcinoma in comparison with squamous cell 
carcinoma.[35-40] A steady decrease in daily smoking prevalence in 
association with switching to low-tar and filter cigarettes (enhancing 
delivery of smoke to peripheral regions of the lung) is believed to 
contribute to the decrease in rates of squamous cell carcinoma and 
the increase in rates of adenocarcinoma.[41-44] It has been postulated 
that filter tips effectively reduce deposition of larger particles in the 
central airway, resulting in a reduced risk of squamous cell carcinoma, 
but increase deposition of small-size particles in the deeper parts of 
the lung where adenocarcinoma preferentially occurs.[41,42]
Study limitations
A limitation of the study is possible selection bias, in that data from 
a single region that only includes <10% of the SA population may 
not be generalisable to the whole population. Furthermore, the lack 
of documentation of race makes it even more difficult to generalise 
the results and findings to the SA population as a whole. Access 
to and quality of healthcare institutions may also vary between 
metropolitan areas. A further potential limitation may be the fact 
that different laboratories were used for analysis and typing of lung 
cancer.
Health insurance type as a measure of SES has limitations in 
that it may be affected by the wide lack of homogeneity within 
each group. In future studies, a multilevel framework examining 
individual and area-specific socioeconomic variables, including 
housing standards, family income, etc., may be a better classification 
of SES. Further, larger-scale studies involving multiple centres (both 
public and privately run) from around the country may aid in proving 
significance of the above findings and minimise any selection bias 
that may be present. A multilevel assessment of SES as outlined above 
may also give a better indication of the true impact of SES on stage of 
presentation with underlying malignancy.
Conclusions
We found a nominal and statistically insignificant difference between 
the stage of presentation in patients who had health insurance 
compared with those who did not have access to private health 
insurance. Larger-scale studies involving multiple centres may need 
to be carried out to identify whether a true difference exists between 
the two groups; this is of great importance, as a difference may have 
important public health implications for the future. It is also evident 
that lung cancer screening as well as other methods to improve early-
stage disease detection remains one of the most important tools in 
improving lung cancer cure rates.
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